Survival of infiltrative hepatocellular carcinoma patients with preserved hepatic function after treatment with transarterial chemoembolization

Journal of Cancer Research and Clinical Oncology

Volumn 139, Issue 4, 2013, Pages 635-643

  Jang, Eun Sun ^a   Yoon, Jung Hwan ^b   Chung, Jin Wook ^b   Cho, Eun Ju ^b   Yu, Su Jong ^b   Lee, Jeong Hoon ^b   Kim, Yoon Jun ^b   Lee, Hyo Suk ^b   Kim, Chung Yong ^b  

^a Seoul National University Bundang Hospital   (South Korea)

^b Seoul National University Hospital   (South Korea)

Author keywords

Carcinoma; Chemoembolization; Hepatocellular; Portal vein pathology; Risk factors; Survival rate; Therapeutic

Indexed keywords

DOXORUBICIN; MITOMYCIN;

ADULT; ARTICLE; ASCITES; BACTERIAL PERITONITIS; BLEEDING; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; FEMALE; FEVER; HUMAN; INFILTRATIVE HEPATOCELLULAR CARCINOMA; LIVER CELL CARCINOMA; LIVER DYSFUNCTION; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; OVERALL SURVIVAL; PARALYTIC ILEUS; PATIENT SAFETY; PATIENT SELECTION; PORTAL VEIN THROMBOSIS; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; SURVIVAL RATE; SURVIVAL TIME; TRANSARTERIAL CHEMOEMBOLIZATION; VARICEAL BLEEDING;

AFTERCARE; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84876410919     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-012-1364-2     Document Type: Article

References (26)

1. Baer HU, Gertsch P, Matthews JB, Schweizer W, Triller J, Zimmermann A, Blumgart LH (1989) Resectability of large focal liver lesions. Br J Surg 76(10):1042-1044
2. Benvegnu L, Noventa F, Bernardinello E, Pontisso P, Gatta A, Alberti A (2001) Evidence for an association between the aetiology of cirrhosis and pattern of hepatocellular carcinoma development. Gut 48(1):110-115
3. Bruix J, Sherman M (2011) Management of hepatocellular carcinoma: an update. Hepatology 53(3):1020-1022. doi: 10.1002/hep.24199
4. Choi SH, Chung JW, Lee HS (2003) Hepatocellular carcinoma supplied by portal flow after repeated transcatheter arterial chemoembolization. AJR Am J Roentgenol 181(3):889-890
5. Chung JW, Park JH, Han JK, Choi BI, Han MC, Lee HS, Kim CY (1996) Hepatic tumors: predisposing factors for complications of transcatheter oily chemoembolization. Radiology 198(1):33-40
6. Chung GE, Lee JH, Kim HY, Hwang SY, Kim JS, Chung JW, Yoon JH, Lee HS, Kim YJ (2011) Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival. Radiology 258(2):627-634. doi: 10.1148/radiol.10101058
7. Conill C, Verger E, Salamero M (1990) Performance status assessment in cancer patients. Cancer 65(8):1864-1866
8. Demirjian A, Peng P, Geschwind JF, Cosgrove D, Schutz J, Kamel IR, Pawlik TM (2011) Infiltrating hepatocellular carcinoma: seeing the tree through the forest. J Gastrointest Surg 15(11):2089-2097. doi: 10.1007/s11605-011-1614-7
9. Forner A, Reig ME, de Lope CR, Bruix J (2010) Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis 30(1):61-74. doi: 10.1055/s-0030-1247133
10. Geschwind JF, Ramsey DE, Choti MA, Thuluvath PJ, Huncharek MS (2003) Chemoembolization of hepatocellular carcinoma: results of a metaanalysis. Am J Clin Oncol 26(4):344-349. doi: 10.1097/01.COC.0000020588.20717.BB
11. Goseki N, Nosaka T, Endo M, Koike M (1995) Nourishment of hepatocellular carcinoma cells through the portal blood flow with and without transcatheter arterial embolization. Cancer 76(5):736-742
12. Kanematsu M, Semelka RC, Leonardou P, Mastropasqua M, Lee JK (2003) Hepatocellular carcinoma of diffuse type: MR imaging findings and clinical manifestations. J Magn Reson Imaging 18(2):189-195. doi: 10.1002/jmri.10336
13. Kiely JM, Rilling WS, Touzios JG, Hieb RA, Franco J, Saeian K, Quebbeman EJ, Pitt HA (2006) Chemoembolization in patients at high risk: results and complications. J Vasc Interv Radiol 17(1):47-53. doi: 10.1097/01.RVI.0000195074. 43474.2F
14. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Sola R, Rodes J, Bruix J (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359(9319):1734-1739. doi: 10.1016/S0140-6736(02)08649-X
15. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4):378-390. doi: 10.1056/ NEJMoa0708857
16. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, Fan ST, Wong J (2002) Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35(5):1164-1171. doi: 10.1053/jhep.2002.33156
17. Lopez RR, Jr, Pan SH, Hoffman AL, Ramirez C, Rojter SE, Ramos H, McMonigle M, Lois J (2002) Comparison of transarterial chemoembolization in patients with unresectable, diffuse vs focal hepatocellular carcinoma. Arch Surg 137(6):653-657; discussion 657-658
18. Marrero JA, Fontana RJ, Barrat A, Askari F, Conjeevaram HS, Su GL, Lok AS (2005) Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology 41(4):707-716. doi: 10.1002/hep.20636
19. Myung SJ, Yoon JH, Kim KM, Gwak GY, Kim YJ, Yu JW, Chung JW, Lee HS (2006) Diffuse infiltrative hepatocellular carcinomas in a hepatitis B-endemic area: diagnostic and therapeutic impediments. Hepatogastroenterology 53(68):266-270
20. Okuda K, Noguchi T, Kubo Y, Shimokawa Y, Kojiro M, Nakashima T (1981) A clinical and pathological study of diffuse type hepatocellular carcinoma. Liver 1(4):280-289
21. Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, Nakajima Y, Ohnishi K (1985) Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 56(4):918-928
22. Sakar B, Ustuner Z, Karagol H, Aksu G, Camlica H, Aykan NF (2004) Prognostic features and survival of inoperable hepatocellular carcinoma in Turkish patients with cirrhosis. Am J Clin Oncol 27(5):489-493
23. Savastano S, Miotto D, Casarrubea G, Teso S, Chiesura-Corona M, Feltrin GP (1999) Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with child's grade A or B cirrhosis: a multivariate analysis of prognostic factors. J Clin Gastroenterol 28(4):334-340
24. Stroffolini T, Andreone P, Andriulli A, Ascione A, Craxi A, Chiaramonte M, Galante D, Manghisi OG, Mazzanti R, Medaglia C, Pilleri G, Rapaccini GL, Albanese M, Taliani G, Tosti ME, Villa E, Gasbarrini G (1999) Gross pathologic types of hepatocellular carcinoma in Italy. Oncology 56(3):189-192
25. Trevisani F, Caraceni P, Bernardi M, D'Intino PE, Arienti V, Amorati P, Stefanini GF, Grazi G, Mazziotti A, Fornale L et al (1993) Gross pathologic types of hepatocellular carcinoma in Italian patients. Relationship with demographic, environmental, and clinical factors. Cancer 72(5):1557-1563
26. Yoon HJ, Kim JH, Kim KA, Lee IS, Ko GY, Song HY, Gwon DI (2010) Transcatheter arterial chemo-lipiodol infusion for unresectable hepatocellular carcinoma in 96 high-risk patients. Clin Radiol 65(4):271-277. doi: 10.1016/j.crad.2010.01.018